HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>PB-119 (T2DM) has the fastest R&amp;D progress, but this is a highly competitive market.China's diabetes drug market is dominated by traditional drugs. It’s not easy for PegBio to break through. </li>
<li>Since the future competitive landscape of GLP-1s (obesity) would present a very different situation.If PB-119 fails to have better weight loss effect, it would be eliminated due to fierce competition.</li>
<li>PegBio’s IPO on SSE STAR Market was rejected. We’re not optimistic about its future commercialization performance. Together with cash-flow issues, we doubt whether PegBio would bring expected returns to investors.</li>
</ul>


PB-119 (T2DM) has the fastest R&amp;D progress, but this is a highly competitive market.China's diabetes drug market is dominated by traditional drugs. It’s not easy for PegBio to break through. 
Since the future competitive landscape of GLP-1s (obesity) would present a very different situation.If PB-119 fails to have better weight loss effect, it would be eliminated due to fierce competition.
PegBio’s IPO on SSE STAR Market was rejected. We’re not optimistic about its future commercialization performance. Together with cash-flow issues, we doubt whether PegBio would bring expected returns to investors.


Pre-IPO PegBio Co., Ltd. - This GLP-1 Biotech Has Gloomy Outlook

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

<ul>
<li>PegBio, a VC-backed biotech company, plans to tap capital markets in Hong Kong. CICC is leading the offering, and an IPO date has yet to be announced.</li>
<li>The company's pipeline features promising drug candidates designed for the treatment of type 2 diabetes mellitus (T2DM), obesity, NASH, OIC and congenital hyperinsulinemia. </li>
<li>PegBio employs a proprietary technology platform, called HECTOR, and has six drug candidates in the pipeline portfolio. PB-119 is their core product with the purpose to treat T2DM and obesity.</li>
</ul>


PegBio, a VC-backed biotech company, plans to tap capital markets in Hong Kong. CICC is leading the offering, and an IPO date has yet to be announced.
The company's pipeline features promising drug candidates designed for the treatment of type 2 diabetes mellitus (T2DM), obesity, NASH, OIC and congenital hyperinsulinemia. 
PegBio employs a proprietary technology platform, called HECTOR, and has six drug candidates in the pipeline portfolio. PB-119 is their core product with the purpose to treat T2DM and obesity.


PegBio IPO Preview: A Founder-Led Biopharma Player Fighting T2DM and Obesity in China

PegBio (PEGBIO HK)

Pre-IPO PegBio Co., Ltd. - This GLP-1 Biotech Has Gloomy Outlook

We doubt whether PegBio can make profits or bring expected returns to investors based on the pipeline situation/competitive landscape. The market...

Xinyao (Criss) Wang

PegBio IPO Preview: A Founder-Led Biopharma Player Fighting T2DM and Obesity in China

PegBio, a promising founder-led biotech company, is seeking to tap capital markets in Hong Kong. Their core product for the treatment of T2DM is at...

Andrei Zakharov